Skip to main content
News

FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists

FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists

Feed excerpt — reported by The Hill

The Food and Drug Administration's (FDA) committee on compounded drugs on Thursday broke with agency scientists and voted in favor of adding peptides to the list of substances compounding pharmacies can make, despite concerns being raised over the lack of demonstrated benefits.  The FDA's Pharmacy Compounding Advisory Committee (PCAC) heard public comments and saw presentation by agency staffers concerning the peptides BPC-157, KPV, TB-500 and MOTS-C. These peptides are purported to help with ulcerative colitis, wound healing, obesity and osteoporosis.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at The Hill →

Original Source

This article was syndicated from The Hill. All rights remain with the original publisher.